Ten Years Application of High-Intensity Focused Ultrasound (Hifu) in Prostate Cancer (Pca) Actuarial Results

Chaussy, C.; Thueroff, S.; Knauer, K.

doi:10.1016/s1569-9056(06)60448-x

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). Studies differentiating low/intermediate‐risk (LR) and high‐risk (HR) patients reported a higher negative prostate biopsy rate in LR than HR patients [10,11,14]. There was no statistically significant difference in negative prostate biopsy rate between patients receiving HIFU alone or a combination of TURP and HIFU [36].…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, it was decided for this review to focus on HIFU as primary therapy for prostate cancer. Considering this, 25 articles/ abstracts evaluating HIFU with the Ablatherm [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][35][36][37][38][39][40][41] and five with the Sonablate device were selected [23][24][25][26][27].…”

Section: Resultsmentioning

confidence: 99%

“…In all, 37 articles/abstracts of studies evaluating the efficacy and/or safety of HIFU in prostate cancer were selected [5–41]. Data on HIFU as salvage therapy after RT were limited; only two fully published papers and five abstracts were identified [28–34].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

Rébillard¹,

Soulié²,

Chartier‐Kastler

et al. 2008

BJU International

103

View full text Add to dashboard Cite

antigen (PSA) level of ≤ 28 ng/mL and a prostate volume of ≤ 40 mL. Negative biopsy rates with the Ablatherm TM device (EDAP TMS S.A., Vaulx-en-Velin, France) were 64-93%, and a PSA nadir of ≤ 0.5 ng/mL was achieved in 55-84% of patients. The 5-year actuarial disease-free survival rates were 60-70%. The most common complications were stress urinary incontinence, urinary tract infection, urethral/bladder neck stenosis or strictures, and erectile dysfunction. For the Ablatherm device, the rate of complications has been significantly reduced over the years, due to technical improvements in the device and the use of transurethral resection of the prostate before HIFU. In conclusion, HIFU as primary therapy for prostate cancer is indicated in older patients ( ≥ 70 years) with T1-T2 N0M0 disease, a Gleason score of < 7, a PSA level of < 15 ng/mL and a prostate volume of < 40 mL. In these patients HIFU achieves short-term cancer control, as shown by a high percentage of negative biopsies and significantly reduced PSA levels. The median-term survival data also seem promising, but long-term follow-up studies are needed to further evaluate cancerspecific and overall survival rates before the indications for primary therapy can be expanded.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

Rébillard¹,

Soulié²,

Chartier‐Kastler

et al. 2008

BJU International

103

View full text Add to dashboard Cite

show abstract

High-intensity Focused Ultrasound for Prostate Cancer: a Systematic Review

Lukka¹,

Waldron²,

Chin³

et al. 2011

Clinical Oncology

View full text Add to dashboard Cite

High-intensity focused ultrasound: where are we and where to from here?

Williams¹,

Martinez²,

Chalasani³

et al. 2010

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) has evolved significantly from early work treating cerebral lesions. The ability to treat deep soft-tissue lesions without damaging superficial structures led to it being used for prostate cancer treatment both in the primary and salvage setting. Primary HIFU treatment for prostate cancer leads to 5-year disease free survival rates of up to 70-80% in selected patients with little morbidity; however, comparative studies with established treatment modalities are lacking. Salvage treatment with HIFU leads to significantly more morbidity than primary treatment yet the morbidity appears the same or less than other salvage treatments following external-beam radiation treatment. We believe that with the development of more advanced imaging techniques combined with multimodality prostate imaging that HIFU's future lies in focal treatment of prostate cancer.

show abstract

Ten Years Application of High-Intensity Focused Ultrasound (Hifu) in Prostate Cancer (Pca) Actuarial Results

Cited by 3 publications

References 0 publications

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

High-intensity Focused Ultrasound for Prostate Cancer: a Systematic Review

High-intensity focused ultrasound: where are we and where to from here?

Contact Info

Product

Resources

About